2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4220 Cryopreserved deceased donor bone marrow as an emergency rescue allograft following unexpected donor unavailability: A multicenter case series

Omer Jamy, MD, Zartash Gul, MD2, Sagar Munjal, MD, MS3, Preethi Prasad4, Vicki L Graves5, Erik J Woods, PhD6, Sumithira Vasu, MBBS., MD7
1 University of Alabama, Birmigham, Alabama, United States
2 Inova schar cancer center, Fairfax, California, United States
3 OSSIUM HEALTH, SAN FRANSISCO, California, United States
4 OSSIUM HEALTH, SAN FRANSISCO, California, United States
5 OSSIUM HEALTH, SAN FRANSISCO, California, United States
6 OSSIUM HEALTH, SAN FRANSISCO, California, United States
7 The Ohio State University, Columbus, Ohio, United States

BACKGROUND

Allogeneic hematopoietic cell transplantation (alloHCT) can be disrupted with detrimental effects for patients when a planned donor graft falls through, especially during or after conditioning before scheduled infusion. In these situations, patients typically face a several-day to multiple-week wait to identify and mobilize a new donor. During this time, prolonged cytopenias carry substantial risks of infection, bleeding, and death. Cryopreserved bone marrow harvested from the vertebral bodies of deceased donors offers an off-the-shelf allograft source that can be selected and shipped within days rather than weeks to mitigate these clinical emergencies. We have previously reported single-patient experiences using this graft source as a rescue strategy. Here, we present a multicenter case series describing outcomes in four patients who received cryopreserved cadaveric bone marrow as an emergency rescue allograft.

METHODS

We report four patients treated across three centers who received an HLA-mismatched, cryopreserved, off-the-shelf bone marrow graft from a deceased donor as a rescue allograft. All four patients had acute myeloid leukemia (AML) in complete remission (CR) at the time of transplant and received myeloablative conditioning All four patients had normal organ function with a Karnofsky Performance Status (KPS) > 70%. Two patients were in the middle of conditioning when the planned donor became unavailable. For one patient, the donor became unavailable on the day of transplant. For one patient, the donor became unavailable prior to the initiation of conditioning, and administering an additional chemotherapy cycle was not preferred.

RESULTS

Median recipient age at HCT was 45 years (Patient 1: 34; Patient 2: 61; Patient 3: 54; Patient 4: 36); two patients were male and two were female, with two in AML CR1 and two in CR2. High-resolution HLA match was 6/8 in Patients 1 and 4, 5/8 in Patient 3, and 4/8 in Patient 2. The four donors had a median age of 42.5 years (Patient 1: 41; Patient 2: 44; Patient 3: 52; Patient 4: 34); Patient 1's donor was female, and the remaining three donors were male. A median of 7.5 bags were infused per patient (Patient 1: 8; Patient 2: 5; Patient 3: 7; Patient 4: 8 bags). The median infused CD34+ cell dose was 3.77 × 10⁶/kg (Patient 1: 5.57; Patient 2: 2.70; Patient 3: 3.45; Patient 4: 4.09 × 10⁶/kg), and the median infused CD3+ cell dose was 2.19 × 10⁷/kg (Patient 1: 4.58; Patient 2: 0.405; Patient 3: 1.02; Patient 4: 3.36 × 10⁷/kg). Median pre-freeze viability was 89.9% (Patient 1: 91.68%; Patient 2: 86.88%; Patient 3: 88.19%; Patient 4: 96.25%).

Neutrophil engraftment was achieved in all four patients at a median of Day 16 (Patient 1: Day 14; Patient 2: Day 19; Patient 3: Day 17; Patient 4: Day 15). Platelet recovery occurred at a median of Day 20 among the three evaluable patients (Patient 1: Day 16; Patient 2: Day 26; Patient 3: Day 20); recovery timing for Patient 4 is pending confirmation at the time of this report.

Grade 1 acute graft-versus-host disease (aGVHD) reported in Patient 1, and Grade 2 aGVHD reproted in Patients 2 and 3. The aGVHD resolved in all cases following systemic treatment.

 No patient developed chronic GVHD, relapse, primary or secondary graft failure, or a serious adverse event related to the Ossium product at the time of this report (follow-up: Patient 1: 383 days; Patient 2: 201 days; Patient 3: 109 days; Patient 4: 46 days post-transplant respectively). All patients remain alive at the time of this report.

CONCLUSIONS

This multicenter case series demonstrates that cryopreserved, off-the-shelf deceased donor bone marrow can serve as an effective emergency rescue graft when a planned donor graft is unexpectedly unavailable. These findings support deceased donor bone marrow as a readily accessible rescue option that can meaningfully shorten time-to-transplant in time-critical clinical emergencies. Continued follow-up and enrollment through the ongoing prospective study (ClinicalTrials.gov NCT05589896) will help further define the long-term safety and durability of this graft source.

Omer Jamy, MD: Ascentage - Consultancy (Includes expert testimony); SELLAS - Consultancy (Includes expert testimony); TERNS - Consultancy (Includes expert testimony)